Lithium Treatment of APPSwDI/NOS2−/− Mice Leads to Reduced Hyperphosphorylated Tau, Increased Amyloid Deposition and Altered Inflammatory Phenotype (original) (raw)
Figure 5
Microglial activation is reduced following lithium treatment.
Panels A and B show CD11b immunocytochemistry in the hippocampus of APPSwDI/NOS2−/− mice receiving either control diet (A) or lithium diet (B) for 8 months. Scale bar in panel A for A and B = 120 µm. Panel C shows quantification of the percent area occupied by positive stain for CD11b in the frontal cortex and hippocampus. Panels D and E show CD45 immunocytochemistry in the hippocampus of APPSwDI/NOS2−/− mice receiving either control diet (D) or lithium diet (E) for 8 months. Scale bar in panel D for D and E = 120 µm. Panel F shows quantification of the percent area occupied by positive stain for CD45 in the frontal cortex and hippocampus. * indicates P<0.05 and ** indicates P<0.01 when compared to APSPwDI/NOS2−/− mice receiving control diet.